Despite challenging times in almost every aspect of health care and the practice of medicine, 150 new medical students will don one of their most identifiable new markers during the White Coat Ceremony for the Class of 2018.
NYU Langone Medical Center Partners with Education Leader Kaplan, Inc., to Improve Patient Care and Save Lives
NYU Langone Medical Center Achieves Honor Roll Status in U.S. News & World Report’s 2014-2015 “Best Hospitals” Ranking
NYU Langone Medical Center Granted Magnet® Status Third Consecutive Time for Excellence in Nursing Services
NEW YORK, June 10, 2014 – The Vein Center at NYU Langone Medical Center announced that it is the first academic medical center to receive official vein center accreditation from the InterSocietal Accreditation Commission (IAC). The accreditation recognizes NYU Langone’s commitment to success in providing quality evaluation, care, and treatment for patients with vein disorders, which affect more than 50 percent of people over the age of 50.
It is no secret that when it comes to taking care of their health, men are notoriously and dangerously neglectful. According to the U.S. Centers for Disease Control and Prevention, men on average die 5.4 years younger than women.
NYU Langone Medical Center raised more than $6.2 million last Thursday night at its annual Violet Ball held at Cipriani on 42nd Street in New York City. This year the president and COO of Goldman Sachs, Gary D. Cohn, who also serves as an NYU Langone trustee and chair of the NYU Langone Musculoskeletal Advisory Board, and his wife Lisa Pevaroff-Cohn, an artist and designer, were honored for their years of dedication to the Medical Center. The funds raised will create full scholarships for talented medical students on behalf of the Cohns.
NYU Langone Medical Center Establishes Office of Therapeutics Alliances to Accelerate Drug Discovery
NYU Langone Medical Center has established a new drug discovery accelerator, the Office of Therapeutics Alliances (OTA). OTA is an innovative, nimble program that advances the discovery of novel therapeutic projects by combining the scientific strengths of NYU Langone investigators in dissecting disease pathways with the expertise of external professional drug discovery and development partners in the biopharma industry.